Synthesis and Antiproliferative Activities of Novel 2-Phenylaminopyrimidine (PAP) Derivatives

Sheng Chang

doi:10.4028/www.scientific.net/AMR.834-836.563

Paper Titles

Solvothermal Synthesis, Structure, Fluorescence and Magnetism Properties of a Novel 3D Metal-Organic Framework Based on Tetranuclear Copper Secondary Building Units
p.543

Calcium Methoxide Synthesis from Quick Lime Using as Solid Catalyst in Refined Palm Oil Biodiesel Production
p.550

Preparation and Characterization of Cellulose Films with Curcumin
p.555

Study the Effect of HAp Content in PLA/HAp Microsphere on the Efficiency of Drug (Clindamycin) Loading Process
p.559

Synthesis and Antiproliferative Activities of Novel 2-Phenylaminopyrimidine (PAP) Derivatives
p.563

The Effect and Mechanism of Apoptosis on Hela Cells Induced by Bufotalin
p.568

Ganoderic Acid Restores the Sensitivity of Multidrug Resistance Cancer Cells to Doxorubicin
p.573

Antioxidant Activities of Flavonoids from Canavalia maritime
p.577

Development of Selective Blue-Laser Lithography for Biomedical Applications: A Pilot Study
p.582

HomeAdvanced Materials ResearchAdvanced Materials Research Vols. 834-836Synthesis and Antiproliferative Activities of...

Synthesis and Antiproliferative Activities of Novel 2-Phenylaminopyrimidine (PAP) Derivatives

Abstract:

A series of novel 2-phenylaminopyrimidine (PAP) derivatives structurally related to Imatinib were designed and synthesized. The abilities of these compounds to inhibit proliferation were tested in human chronicmyeloid leukemia K562 cells and HL60cells. Compound (10c) was the most effective cell growth inhibitor in inhibiting K562 cells and compound (10f) was the most effective cell growth inhibitor in inhibiting HL60 cells.

You might also be interested in these eBooks

Research in Materials and Manufacturing Technologies

View Preview

Info:

Periodical:

Advanced Materials Research (Volumes 834-836)

Pages:

563-567

DOI:

https://doi.org/10.4028/www.scientific.net/AMR.834-836.563

Citation:

Cite this paper

Online since:

October 2013

Authors:

Sheng Chang*

Keywords:

2-Phenylaminopyrimidine (PAP) Derivative, Antiproliferative Activity

Export:

RIS, BibTeX

Price:

Permissions CCC:

Request Permissions

Permissions PLS:

Request Permissions

Сopyright:

Citation:

* - Corresponding Author

References

[1] M. Warmuth, S. D. Riedl, M. Hallek, Molecular pathogenesis of chronic myeloid leukemia: Implications for new therapeutic strategies, J. Ann. Hematol. 78 (1999) 49–64.

DOI: 10.1007/s002770050473

Google Scholar

[2] J. E. Cortes, M. Talpaz, H. KantarJian, Chronic myelogenous leukemia: A review, J. Am. J. Med. 100 (1996) 555–570.

DOI: 10.1016/s0002-9343(96)00061-7

Google Scholar

[3] P. C. Nowell, D. A. Hungerford, A minute chromosome in human chronic granulocytic leukemia, J. Science. 132 (1960) 1497–1501.

DOI: 10.1016/b978-012448510-5.50134-5

Google Scholar

[4] J. D. Rowley, A new consistent chromosmal abnormality in chronic myelgenous leukemia identified by quinacrine fluorescence and Giemsa staining, J. Nature. 243 (1973) 290–293.

DOI: 10.1038/243290a0

Google Scholar

[5] S. Wong, O. N. Witte, The BCR-ABL story: Bench to beside and back, J. Annu. Rev. Immunol. 22, (2004) 247–306.

DOI: 10.1146/annurev.immunol.22.012703.104753

Google Scholar

[6] C. C. Lucy, O'B. Stephen, Clinical results with imatinib in chronic myeloid leukaemia, J. Leukemia Research. Supplement1 (2004) 3-9.

Google Scholar

[7] B. Massimo, E. Fabio, A. Giuliana, Imatinib treatment in chronic myelogenous leukemia: What have we learned so far?, J. Cancer. Letters. 300 (2011) 115-121.

DOI: 10.1016/j.canlet.2010.10.018

Google Scholar

[8] S. B. Brady, S. Douglas, Treatment options for patients with chronic myeloid leukemia who are resistant to or unable to tolerate imatinib, J. Clinical Therapeutics. 32 (2010) 804-820.

DOI: 10.1016/j.clinthera.2010.05.003

Google Scholar

[9] C. Roche-Lestienne, V. Soenen-Cornu, N. Grardel-Duflos, J. L . Laï, N. Philippe, T. Facon, P. Febaux, C. Preudhomme, Several types of mutations of the Abl can be found in chronic meloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment, J. Blood. 100 (2002).

DOI: 10.1182/blood.v100.3.1014

Google Scholar

[10] M. E. Gorre, M. Mohammed, K. Ellwood, N .H. Su, R. Paquette, P. N. Rao, C. L. Sawyers, Mechanisms of resistance to BCR-ABL and other kinase inhibitors, J. Biochimica et Biophysica Acta (BBA) Proteins and Proteomics. 1834 (2013) 1449-1459.

DOI: 10.1016/j.bbapap.2012.12.009

Google Scholar

[11] S Chang, S. L. Yin, J. Wang, Y. K. Jing, J. H. Dong, Design and Synthesis of Novel 2-Phenylamin-opyrimidine (PAP) Derivatives and Their Antiproliferative Effects in Human Chronic Myeloid Leukemia Cells, J. Molecules. 14 (2009) 4166-4179.

DOI: 10.3390/molecules14104166

Google Scholar